"Pathios Therapeutics Raises $25M in Series B Funding to Advance Cancer Immunotherapy Development"

Pathios Therapeutics' Series B Funding

Key Highlights:

• Series B Funding: Raised $25 million in the first close of Series B funding.
• Investors: Backed by Bristol Myers Squibb, Canaan, and Brandon Capital.
• Immunotherapy Development: Funds will be used to further develop Pathios' approach to cancer immunotherapy, focusing on inhibiting GPR65.

Pathios Therapeutics' Target Market

• Target Market: Biotech and pharmaceutical companies involved in cancer research and immunotherapy development.
• Cancer Research Institutions: Collaborations with research institutions focused on understanding and treating cancer.
• Pharmaceutical Companies: Partnerships with pharmaceutical companies interested in developing innovative cancer therapies.

What Pathios Therapeutics Needs to Buy

• Research and Development Services: Collaborations with research organizations and service providers for further development of cancer immunotherapy approaches.
• Manufacturing and Supply Chain Solutions: Partnerships with manufacturers to produce small molecule inhibitors for GPR65.
• Regulatory and Clinical Expertise: Engaging with regulatory consultants and clinical research organizations for navigating the drug development process.